The human immunodeficiency virus (HIV) is a lentivirus (a subgroup of retrovirus) that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS).AIDS is a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive.
The key factors responsible for driving the market growth include the increasing incidence of HIV infections especially amongst the youth due to unprotected sexual practices, exposure to needles or syringes contaminated with infected body fluids or tissues, lack of awareness regarding transmission risk factors, etc.

Market Analysis and Insights: Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
The global Human Immunodeficiency Virus (HIV)-1 Therapeutics market size is projected to reach US$ 12560 million by 2027, from US$ 11880 million in 2020, at a CAGR of 0.8% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market.

Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Scope and Market Size
Human Immunodeficiency Virus (HIV)-1 Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry and Fusion Inhibitors
Protease Inhibitors (PIs)
Integrase Inhibitors
Coreceptor Antagonists

Segment by Application
Hospitals
Clinics
Labs

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AbbVie, Inc.(U.S.)
Merck & Co., Inc. (U.S.)
Bristol-Myers Squibb Company (U.S.)
Boehringer Ingelheim GmbH (Germany)
Genentech, Inc. (U.S.)
Cipla, Inc. (India)